![Laura Cassin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Laura Cassin
Private Equity Analist bij
Nimbus Synergies, Inc.
Profiel
Laura Cassin is an Investment Analyst at Nimbus Synergies, Inc. since 2017.
She completed her undergraduate degree from the University of Victoria in 1998.
Actieve functies van Laura Cassin
| Bedrijven | Functie | Begin |
|---|---|---|
Nimbus Synergies, Inc.
 Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies invests in companies located in North America primarily in Canada and opportunistically in the United States with revenues of USD 0.5 - 2 million. The firm focuses on the health technology sector. It participates in pre-seed, seed and early stage capital requirements with an investment size of USD 0.25 - 5 million. The firm makes co-investments and also acts as a lead investor. It takes a seat on the board of directors. The firm makes follow-on investments and it does not invest in therapeutics and class III devices. | Private Equity Analist | 01-06-2017 |
Opleiding van Laura Cassin
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
77
Eerstegraads connecties
2
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
University of Victoria
 University of Victoria Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nimbus Synergies, Inc.
Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies invests in companies located in North America primarily in Canada and opportunistically in the United States with revenues of USD 0.5 - 2 million. The firm focuses on the health technology sector. It participates in pre-seed, seed and early stage capital requirements with an investment size of USD 0.25 - 5 million. The firm makes co-investments and also acts as a lead investor. It takes a seat on the board of directors. The firm makes follow-on investments and it does not invest in therapeutics and class III devices. | Finance |
